JPH06192209A - Method for purifying taurine - Google Patents

Method for purifying taurine

Info

Publication number
JPH06192209A
JPH06192209A JP34633192A JP34633192A JPH06192209A JP H06192209 A JPH06192209 A JP H06192209A JP 34633192 A JP34633192 A JP 34633192A JP 34633192 A JP34633192 A JP 34633192A JP H06192209 A JPH06192209 A JP H06192209A
Authority
JP
Japan
Prior art keywords
taurine
alcohol
solution
impurities
crystals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP34633192A
Other languages
Japanese (ja)
Other versions
JP3080801B2 (en
Inventor
Kiyoshi Ito
伊藤  潔
Daisuke Ura
大輔 浦
Makoto Yanaka
誠 谷中
Nobuhiro Fukuhara
信裕 福原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsui Toatsu Chemicals Inc
Original Assignee
Mitsui Toatsu Chemicals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsui Toatsu Chemicals Inc filed Critical Mitsui Toatsu Chemicals Inc
Priority to JP04346331A priority Critical patent/JP3080801B2/en
Publication of JPH06192209A publication Critical patent/JPH06192209A/en
Application granted granted Critical
Publication of JP3080801B2 publication Critical patent/JP3080801B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

PURPOSE:To separate or remove impurities and obtain high-purity taurine having wide uses as a medicine such as a therapeutic agent for hepatopathy, an antidote or an anticonvulsant agent or a food additive in high yield simply by treating the taurine in an alcoholic solution. CONSTITUTION:Crude taurine (2-aminoethylsulfonic acid) obtained especially by a method for reacting 2-chloroethylamine hydrochloride with sodium sulfite, etc., is treated in an alcoholic solution to separate or remove impurities. Methanol and ethanol are preferred as the alcohol to be used. The final concentration of the alcohol in carrying out this treatment is >=20wt.%, preferably >=35wt.%. The crystallization temperature is preferably <=10 deg.C.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、タウリン(2−アミノ
エチルスルホン酸)の精製法に関する。更に詳細には、
製造工程を通して得られるタウリンを精製するに際し
て、アルコール溶液で処理するタウリンの精製法に関す
る。
FIELD OF THE INVENTION The present invention relates to a method for purifying taurine (2-aminoethylsulfonic acid). More specifically,
The present invention relates to a method for purifying taurine, which comprises treating with an alcohol solution when purifying taurine obtained through a manufacturing process.

【0002】[0002]

【従来の技術および発明が解決しようとする課題】タウ
リンは、肝臓疾患治療薬・解毒剤・抗けいれん薬等の薬
剤や食品添加物としての用途が広く知られている。
BACKGROUND OF THE INVENTION Taurine is widely known as a drug such as a drug for treating liver diseases, an antidote, an anticonvulsant, and a food additive.

【0003】タウリンの製法としては、水産物からの抽
出や複数の有機合成法が既に知られているが、上述の用
途に供するためには、タウリンを高純度に精製しなけれ
ばならない。また、工業的には、タウリンを高収率で得
ることも重要である。
As a method for producing taurine, extraction from aquatic products and a plurality of organic synthesis methods are already known, but taurine must be purified to a high degree of purity in order to be used in the above applications. Further, industrially, it is important to obtain taurine in a high yield.

【0004】タウリンを高収率で精製する手段として
は、従来より、アルコールを添加して晶析を行う技術が
知られている。すなわち、天然物(水産物等)の熱水ま
たは温水抽出溶液や合成反応終了液よりタウリンを精製
する際に、アルコール水溶液中でタウリンの結晶を析出
させ、濾過・乾燥により最終的なタウリン結晶を得る方
法である。
As a means for purifying taurine in a high yield, a technique of adding alcohol for crystallization has been known. That is, when purifying taurine from a hot water or hot water extraction solution of natural products (aquatic products, etc.) or a synthetic reaction completed solution, crystals of taurine are precipitated in an aqueous alcohol solution, and final taurine crystals are obtained by filtration and drying. Is the way.

【0005】しかし、天然物からタウリンを精製する場
合は、不特定多数の不純物が多量に存在しているので、
アルコール処理時の不純物の共沈を避けることはできな
い。このため、前もって電気透析処理やイオン交換樹脂
処理等を行って、晶析前にある程度の不純物を除去しな
ければならない。
However, in the case of purifying taurine from natural products, a large number of unspecified impurities are present,
Coprecipitation of impurities during alcohol treatment cannot be avoided. Therefore, it is necessary to remove impurities to some extent before crystallization by performing electrodialysis treatment or ion exchange resin treatment in advance.

【0006】一方、製造工程を通して得られるタウリン
を精製する場合は、存在する不純物の種類・量が限られ
てくるので、特定の不純物の除去に的を絞った晶析によ
り、精製を行うことが可能である。
On the other hand, in the case of purifying taurine obtained through the manufacturing process, the types and amounts of impurities present are limited, so that purification can be performed by crystallization focused on the removal of specific impurities. It is possible.

【0007】タウリンを製造する有機合成法について
は、従来より数種類の方法が知られているが、その代表
例として、2−クロルエチルアミン塩酸塩と亜硫酸ナト
リウムを反応させてタウリンを製造する方法を挙げるこ
とができる(特開昭60−23360、特開昭60−2
3361、特開昭63−48258、特開昭63−48
259)。
Several types of organic synthesis methods for producing taurine have been known, and a typical example thereof is a method for producing taurine by reacting 2-chloroethylamine hydrochloride with sodium sulfite. (JP-A-60-23360, JP-A-60-2)
3361, JP-A-63-48258, JP-A-63-48
259).

【0008】本法の場合、タウリンの生成に際して、2
倍モル量の塩化ナトリウムが副生するので、反応終了液
(以下、反応液と呼称)中には、タウリンとほぼ同重量
濃度の塩化ナトリウムが存在している。また、原料であ
る亜硫酸ナトリウム中に含まれる硫酸ナトリウムおよび
亜硫酸ナトリウムの酸化により副生する硫酸ナトリウム
も反応液中に含有されている。さらに、原料である2−
クロルエチルアミン(以下、CEA)、CEAの原料で
ある2−アミノエタノール(以下、MEA)、CEAま
たはMEAとタウリンが反応して生成するN−(2−ア
ミノエチル)−タウリン(以下、AET)、MEA2分
子が脱水縮合して生じるオキシビス−アミノエタン(以
下、OBAE)等の不純物が存在している。
In the case of this method, when taurine is produced, 2
Since a double molar amount of sodium chloride is by-produced, sodium chloride having almost the same weight concentration as that of taurine is present in the reaction completed solution (hereinafter referred to as the reaction solution). Further, sodium sulfate contained in the raw material sodium sulfite and sodium sulfate by-produced by the oxidation of sodium sulfite are also contained in the reaction liquid. Furthermore, the raw material 2-
Chlorethylamine (hereinafter, CEA), 2-aminoethanol (hereinafter, MEA) that is a raw material of CEA, N- (2-aminoethyl) -taurine (hereinafter, AET) produced by the reaction of CEA or MEA and taurine, Impurities such as oxybis-aminoethane (hereinafter, OBAE) produced by dehydration condensation of two MEA molecules are present.

【0009】ここで、アルコール、特に水と任意に混和
する低級アルコールは、汎用性が高く工業的に広く利用
されている溶媒である。その理由の一つは、水溶液中と
アルコール水溶液中では、溶解度に代表されるような個
々の化合物の物性に変化が生じることである。本発明者
らは、アルコール溶液中では、上記の不純物の挙動に変
化が生じるのではないかと考え、検討を行い本発明を完
成させた。
Here, alcohol, especially lower alcohol optionally mixed with water, is a solvent that is highly versatile and widely used in industry. One of the reasons is that the physical properties of individual compounds represented by the solubility change in the aqueous solution and the aqueous alcohol solution. The inventors of the present invention considered that the behavior of the above impurities might change in an alcohol solution, and conducted studies and completed the present invention.

【0010】[0010]

【課題を解決するための手段】本研究者らは、上記不純
物群についてアルコール溶液中での溶解度の検討を行っ
た。その結果、タウリンと同様に塩化ナトリウム・亜硫
酸ナトリウム・硫酸ナトリウム・AETは、アルコール
濃度が高くなるとその飽和溶解度が顕著に減じるのに対
して、CEA・MEA・OBAEは、アルコール濃度に
飽和溶解度があまり依存しないことが判明した。さら
に、CEA・MEA・OBAEは、アルコール溶液中で
タウリンを晶析させた場合、タウリン結晶中への巻き込
みが少なくなるという性質を見いだした。そこで、各不
純物とタウリンのアルコール溶液中での挙動の差を利用
した本発明を完成させるに至った。
[Means for Solving the Problems] The present inventors investigated the solubility of the above impurity groups in an alcohol solution. As a result, like taurine, sodium chloride / sodium sulfite / sodium sulfate / AET has a significantly reduced saturated solubility when the alcohol concentration is high, whereas CEA / MEA / OBAE has a very low saturated solubility in the alcohol concentration. Turned out to be independent. Furthermore, CEA / MEA / OBAE was found to have a property that when taurine was crystallized in an alcohol solution, entrainment in taurine crystals was reduced. Therefore, the present invention was completed by utilizing the difference in behavior between each impurity and taurine in the alcohol solution.

【0011】すなわち、本発明は、製造工程を通して得
られるタウリンを、アルコール溶液で処理して、不純物
を分離または除去することを特徴とするタウリンの精製
法である。さらに、かかる製造工程が2−クロルエチル
アミン塩酸塩と亜硫酸ナトリウムを反応させるものであ
る場合には、特に有効な精製法である。
That is, the present invention is a method for purifying taurine, which comprises treating taurine obtained through a manufacturing process with an alcohol solution to separate or remove impurities. Furthermore, when such a manufacturing process is a reaction of 2-chloroethylamine hydrochloride and sodium sulfite, it is a particularly effective purification method.

【0012】以下、本発明の実施方法に関して、詳細に
記述する。本発明のタウリンの製造工程に関しては何ら
限定されないが、以下に挙げる有機合成法に従って製造
される場合には、上述の不純物が反応液中に存在してい
るので特に有効な方法である。 イ) 2−クロルエチルアミン塩酸塩と亜硫酸ナトリウ
ムを反応させて製造する方法(Ind.Eng.Che
m.,Vol.39,1947、特公昭63−4825
8、特公昭63−48259)。 ロ) 2−ブロムエチルアミン臭化水素塩と亜硫酸ナト
リウムを反応させて製造する方法(J.Am.Che
m.Soc.,vol.58,1936)。 ハ) 2−アミノエタノール硫酸エステルと亜硫酸ナト
リウムを反応させて製造する方法(J.Chem.So
c.,vol.4,1943、特公平4−1046
7)。 ニ) 2,2−2置換チアゾリジンを酸化して製造する
方法(特開昭57−26654)。
The method for carrying out the present invention will be described in detail below. The production process of taurine of the present invention is not particularly limited, but it is a particularly effective method when it is produced according to the organic synthesis method described below, because the above-mentioned impurities are present in the reaction solution. B) A method of producing by reacting 2-chloroethylamine hydrochloride with sodium sulfite (Ind. Eng. Che
m. , Vol. 39, 1947, JP-B-63-4825
8, Japanese Patent Publication No. 63-48259). B) A method for producing by reacting 2-bromoethylamine hydrobromide with sodium sulfite (J. Am. Che
m. Soc. , Vol. 58, 1936). C) A method of reacting 2-aminoethanol sulfate with sodium sulfite to produce (J. Chem. So.
c. , Vol. 4,1943, Japanese Examined Patent Publication 4-1046
7). D) A method for producing a 2,2-2 substituted thiazolidine by oxidation (JP-A-57-26654).

【0013】本発明は、具体的には、上記の反応液にア
ルコールを添加してタウリンを晶析させ、結晶を濾過等
の手段により分離することで達成される。この際、CE
A・MEA・OBAE等の不純物は、タウリン結晶中に
巻き込まれにくくなるので、タウリンと効率よく分離す
ることができる。さらに、この性質は、処理時のアルコ
ールの濃度に関しては何ら限定されないが、好ましくは
20重量%以上の濃度で実施するのが効果的である。ま
た、アルコールの種類・晶析温度に関しては、何ら限定
されない。
The present invention is specifically achieved by adding alcohol to the above reaction solution to crystallize taurine and separating the crystals by means such as filtration. At this time, CE
Impurities such as A, MEA, and OBAE are less likely to be trapped in the taurine crystal, and thus can be efficiently separated from taurine. Further, this property is not limited at all with respect to the concentration of alcohol during the treatment, but it is effective to carry out it at a concentration of preferably 20% by weight or more. Further, there is no limitation on the type of alcohol and the crystallization temperature.

【0014】工業的には、反応液からタウリンを収率よ
く取得することが重要である。このため、本発明の処理
を行う際のアルコール終濃度に関しては、20重量%以
上、好ましくは35重量%以上が望ましく、晶析温度に
関しては、20℃以下、好ましくは10℃以下が望まし
い。アルコールに関しては、水と任意に混和するもので
あれば特に限定されないが、特にメタノールまたはエタ
ノールが望ましい。
Industrially, it is important to obtain taurine from the reaction solution in good yield. Therefore, the final concentration of alcohol when the treatment of the present invention is performed is preferably 20% by weight or more, preferably 35% by weight or more, and the crystallization temperature is preferably 20 ° C. or lower, preferably 10 ° C. or lower. The alcohol is not particularly limited as long as it is freely miscible with water, but methanol or ethanol is particularly desirable.

【0015】CEA・MEA・OBAE等の不純物と分
離されたタウリン結晶が、その溶解度がアルコール濃度
に依存する塩化ナトリウム・亜硫酸ナトリウム・硫酸ナ
トリウム・AET等の不純物を含んでいる場合には、水
溶液または20重量%未満のアルコール水溶液中で、再
結晶またはスラッジング等を行うことにより、これらの
化合物とタウリンとの分離が最終的に可能となる。
When the taurine crystal separated from impurities such as CEA / MEA / OBAE contains impurities such as sodium chloride / sodium sulfite / sodium sulfate / AET whose solubility depends on the alcohol concentration, an aqueous solution or Recrystallization or sludging or the like is performed in an alcohol aqueous solution of less than 20% by weight to finally separate these compounds from taurine.

【0016】ここで、実施例と比較例を用いて、本発明
の効果を具体的に説明する。実施例では、最終的な再結
を行う前に、2回のメタノール溶液中での晶析により、
反応液中の特定の不純物(MEA・CEA・OBAE)
を除去している。これに対して、比較例では、実施例で
除去できた不純物を完全には除去できない上に、不純物
含有量も相対的に多くなっている。
Here, the effects of the present invention will be specifically described by using Examples and Comparative Examples. In the examples, before performing the final reconstitution, two crystallizations in methanol solution
Specific impurities in the reaction solution (MEA, CEA, OBAE)
Have been removed. On the other hand, in the comparative example, the impurities that could be removed in the examples cannot be completely removed, and the impurity content is relatively large.

【0017】また、実施例の二次晶と比較例の一次晶を
比べると、比較例の収率は実施例よりも低くなってお
り、これが最終的な収率に影響を与えている。
When the secondary crystal of the example and the primary crystal of the comparative example are compared, the yield of the comparative example is lower than that of the example, which affects the final yield.

【0018】[0018]

【実施例】【Example】

実施例 特開昭63−48259で示された方法により合成され
たタウリン反応液400.0gを用いて精製を行った。
この溶液中の各化合物の量は、以下のとおりであった。 タウリン 76.0g 塩化ナトリウム 71.0g 硫酸ナトリウム 6.2g AET 2.73g MEA 2.79g CEA 0.67g OBEA 3.12g 反応液を一度70℃に加温し、タウリン等を完全に溶解
させた。室温まで冷却した後、メタノール267.0g
を徐々に添加(メタノール濃度40.0重量%)し、0
℃で2時間かく拌してタウリン結晶を析出させ、濾過・
分離・乾燥により一次晶101.1gを得た。一次晶中
の化合物の量は、以下のとおりであった(カッコ内は、
反応液からの収率) タウリン 71.3g (93.8%) 塩化ナトリウム 26.2g (36.9%) 硫酸ナトリウム 2.8g (44.4%) AET 0.27g( 9.9%) MEA 0.02g( 0.7%) CEA 未検出 ( 0.0%) OBEA 未検出 ( 0.0%) 続いて、一次晶に水127.1gを加えて80℃に加温
し、一次晶を完全に溶解させた。室温まで冷却した後、
メタノール57.0gを徐々に添加(メタノール濃度2
0.0重量%、タウリン濃度25.0重量%)し、10
℃で2時間撹拌してタウリン結晶を析出させ、濾過・分
離・乾燥により二次晶66.4gを得た。二次晶中の化
合物の量は、以下のとおりであった(カッコ内は、反応
液からの総合収率)。 タウリン 65.5g (86.2%) 塩化ナトリウム 0.76g( 1.1%) 硫酸ナトリウム 0.03g( 0.5%) AET 0.04g( 1.4%) MEA 未検出 ( 0.0%) さらに、二次晶に水159.6gを加えて80℃に加温
し、二次晶を完全に溶解させた(タウリン濃度29.0
w%)。10℃で2時間撹拌してタウリン結晶を析出さ
せ、濾過・分離・乾燥により三次晶53.5gを得た。
この三次晶中には、AETは含まれていなかった。ま
た、日本薬局方(第八改正)合格品であった(タウリン
純度99.7%)。反応液からの総合収率は、70.4
%であった。なお、実施例・比較例ともに、タウリン・
MEA・CEA・AET・OBAEの定量分析は、高速
液体クロマトグラフィーを用いて、以下の分析方法およ
び条件で行った。 カラム:Inersitol ODS−2 キャリアー:10v%メタノール−30mMリン酸水溶
液(pH3.0) (ただし、0.6重量% 1−ヘプタンスルホン酸含
有) 流速:1.0ml/min カラム温度:40℃ 検出法:o−フタルアルデヒドによる蛍光法(EX=3
65nm,EM=455nm) 検出限界:1ppm また、塩化ナトリウムおよび硫酸ナトリウムの定量分析
は、それぞれ塩素イオンおよび硫酸イオンについて、D
IONEX社のイオンクロマトグラフィー装置シリーズ
2000i(カラム:AS4A)を用いて行った。
Example Purification was carried out using 400.0 g of a taurine reaction solution synthesized by the method disclosed in JP-A-63-48259.
The amount of each compound in this solution was as follows. Taurine 76.0 g Sodium chloride 71.0 g Sodium sulfate 6.2 g AET 2.73 g MEA 2.79 g CEA 0.67 g OBEA 3.12 g The reaction solution was once heated to 70 ° C. to completely dissolve taurine and the like. After cooling to room temperature, 267.0 g of methanol
Is gradually added (methanol concentration 40.0% by weight), and 0
The mixture was stirred at ℃ for 2 hours to precipitate taurine crystals and filtered.
Separation and drying gave 101.1 g of primary crystals. The amount of the compound in the primary crystal was as follows (in parentheses:
Yield from reaction solution) Taurine 71.3 g (93.8%) Sodium chloride 26.2 g (36.9%) Sodium sulfate 2.8 g (44.4%) AET 0.27 g (9.9%) MEA 0.02 g (0.7%) CEA non-detection (0.0%) OBEA non-detection (0.0%) Subsequently, 127.1 g of water was added to the primary crystal and the mixture was heated to 80 ° C. to form the primary crystal. It was completely dissolved. After cooling to room temperature,
Slowly add 57.0 g of methanol (methanol concentration 2
0.0 wt%, taurine concentration 25.0 wt%), then 10
The mixture was stirred at ℃ for 2 hours to precipitate taurine crystals, which were filtered, separated and dried to obtain 66.4 g of secondary crystals. The amount of the compound in the secondary crystal was as follows (in parentheses, the total yield from the reaction solution). Taurine 65.5 g (86.2%) Sodium chloride 0.76 g (1.1%) Sodium sulfate 0.03 g (0.5%) AET 0.04 g (1.4%) MEA undetected (0.0% Further, 159.6 g of water was added to the secondary crystal and heated to 80 ° C. to completely dissolve the secondary crystal (taurine concentration 29.0).
w%). The mixture was stirred at 10 ° C. for 2 hours to precipitate taurine crystals, which was filtered, separated and dried to obtain 53.5 g of tertiary crystals.
AET was not contained in this tertiary crystal. In addition, it was a product that passed the Japanese Pharmacopoeia (8th revision) (taurine purity 99.7%). The total yield from the reaction solution is 70.4.
%Met. In both the examples and comparative examples, taurine
Quantitative analysis of MEA / CEA / AET / OBAE was performed using high performance liquid chromatography under the following analysis method and conditions. Column: Inersitol ODS-2 Carrier: 10v% methanol-30mM phosphoric acid aqueous solution (pH 3.0) (however, containing 0.6% by weight 1-heptanesulfonic acid) Flow rate: 1.0ml / min Column temperature: 40 ° C Detection method : Fluorescence method with o-phthalaldehyde (EX = 3
(65 nm, EM = 455 nm) Detection limit: 1 ppm Further, the quantitative analysis of sodium chloride and sodium sulfate was carried out by measuring D for chlorine ion and sulfate ion, respectively.
It was performed using an ion chromatography device series 2000i (column: AS4A) manufactured by IONEX.

【0019】比較例 実施例1と同じ溶液400.0gを用いて、タウリンの
精製を行った。反応液を一度70℃に加温し、タウリン
等を完全に溶解させた。室温まで冷却した後、10℃で
2時間撹拌してタウリン結晶を析出させ、濾過・分離・
乾燥により一次晶54.2gを得た。一次晶中の化合物
の量は、以下のとおりであった(カッコ内は、晶析母液
からの収率) タウリン 51.8g (68.2%) 塩化ナトリウム 1.6g ( 2.3%) 硫酸ナトリウム 0.18g( 2.9%) AET 0.11g( 4.0%) MEA 0.17g( 6.1%) CEA 0.04 ( 6.0%) OBEA 0.12 ( 3.8%) 続いて、一次晶に水124.4gを加えて80℃に加温
し、一次晶を完全に溶解させた(タウリン濃度29.0
重量%)。室温まで冷却した後、10℃で2時間撹拌し
てタウリン結晶を析出させ、濾過・分離・乾燥により二
次晶42.3gを得た。この二次晶は、日本薬局方(第
八改正)合格品であった(タウリン純度99.7%)。
反応液からの総合収率は、55.7%であった。
Comparative Example 400.0 g of the same solution as in Example 1 was used to purify taurine. The reaction solution was once heated to 70 ° C. to completely dissolve taurine and the like. After cooling to room temperature, stirring at 10 ° C for 2 hours to precipitate taurine crystals, filtration, separation,
By drying, 54.2 g of primary crystals were obtained. The amount of the compound in the primary crystal was as follows (in parentheses, the yield from the crystallization mother liquor) Taurine 51.8 g (68.2%) Sodium chloride 1.6 g (2.3%) Sulfuric acid Sodium 0.18g (2.9%) AET 0.11g (4.0%) MEA 0.17g (6.1%) CEA 0.04 (6.0%) OBEA 0.12 (3.8%) Subsequently, 124.4 g of water was added to the primary crystal and heated to 80 ° C. to completely dissolve the primary crystal (taurine concentration 29.0).
weight%). After cooling to room temperature, the mixture was stirred at 10 ° C. for 2 hours to precipitate taurine crystals, and filtered, separated and dried to obtain 42.3 g of secondary crystals. This secondary crystal was a product that passed the Japanese Pharmacopoeia (eighth revision) (taurine purity 99.7%).
The overall yield from the reaction solution was 55.7%.

【0020】[0020]

【発明の効果】本発明方法により、製造工程を通して得
られるタウリンを精製するに際して、製造過程で副生す
る不純物を効率よく分離し、かつタウリンを高収率で得
ることが可能となった。
According to the method of the present invention, when purifying taurine obtained through the production process, it is possible to efficiently separate impurities by-produced in the production process and obtain taurine in a high yield.

───────────────────────────────────────────────────── フロントページの続き (72)発明者 福原 信裕 福岡県大牟田市浅牟田町30 三井東圧化学 株式会社内 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Nobuhiro Fukuhara 30 Asamu-cho, Omuta-shi, Fukuoka Mitsui Toatsu Chemical Co., Ltd.

Claims (4)

【特許請求の範囲】[Claims] 【請求項1】 製造工程を通して得られるタウリンを、
アルコール溶液中で処理して、不純物を分離または除去
することを特徴とするタウリンの精製法
1. Taurine obtained through the manufacturing process,
Method for purifying taurine, characterized by treatment in alcoholic solution to separate or remove impurities
【請求項2】 製造工程が、2−クロルエチルアミン塩
酸塩と亜硫酸ナトリウムを反応させるものである場合の
請求項1の精製法。
2. The purification method according to claim 1, wherein the production step is a reaction of 2-chloroethylamine hydrochloride with sodium sulfite.
【請求項3】 処理するアルコール溶液の終濃度が、2
0重量%以上である請求項1または請求項2の精製法
3. The final concentration of the alcohol solution to be treated is 2
The purification method according to claim 1 or 2, which is 0% by weight or more.
【請求項4】 処理に用いるアルコールがメタノールま
たはエタノールである請求項1または請求項2または請
求項3の精製法。
4. The purification method according to claim 1, 2 or 3, wherein the alcohol used for the treatment is methanol or ethanol.
JP04346331A 1992-12-25 1992-12-25 Taurine purification method Expired - Lifetime JP3080801B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP04346331A JP3080801B2 (en) 1992-12-25 1992-12-25 Taurine purification method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP04346331A JP3080801B2 (en) 1992-12-25 1992-12-25 Taurine purification method

Publications (2)

Publication Number Publication Date
JPH06192209A true JPH06192209A (en) 1994-07-12
JP3080801B2 JP3080801B2 (en) 2000-08-28

Family

ID=18382690

Family Applications (1)

Application Number Title Priority Date Filing Date
JP04346331A Expired - Lifetime JP3080801B2 (en) 1992-12-25 1992-12-25 Taurine purification method

Country Status (1)

Country Link
JP (1) JP3080801B2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160119013A (en) * 2014-12-16 2016-10-12 변종현 A modified taurine and a pharmaceutical composition containing the same for prevention or treatment of metabolic disease
WO2023199995A1 (en) 2022-04-15 2023-10-19 コスメディ製薬株式会社 Skin external agent composition in which fine needle-like or columnar crystals of taurine are blended
WO2023210059A1 (en) 2022-04-25 2023-11-02 コスメディ製薬株式会社 Dermatological topical agent composition containing useful component-including taurine crystals

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160119013A (en) * 2014-12-16 2016-10-12 변종현 A modified taurine and a pharmaceutical composition containing the same for prevention or treatment of metabolic disease
WO2023199995A1 (en) 2022-04-15 2023-10-19 コスメディ製薬株式会社 Skin external agent composition in which fine needle-like or columnar crystals of taurine are blended
KR20250004655A (en) 2022-04-15 2025-01-08 코스메드 파마소티컬 씨오 쩜 엘티디 Composition for external skin application containing fine needle-shaped or columnar crystals of taurine
WO2023210059A1 (en) 2022-04-25 2023-11-02 コスメディ製薬株式会社 Dermatological topical agent composition containing useful component-including taurine crystals
KR20240001707A (en) 2022-04-25 2024-01-03 코스메드 파마소티컬 씨오 쩜 엘티디 Composition for external use on skin containing taurine crystals containing useful ingredients

Also Published As

Publication number Publication date
JP3080801B2 (en) 2000-08-28

Similar Documents

Publication Publication Date Title
US4894476A (en) Gabapentin monohydrate and a process for producing the same
PT1334963E (en) Process for producing nateglinide crystal
JPS58146560A (en) Salicyl derivative of n-acetylcystein, manufacture and drug
JPH06192209A (en) Method for purifying taurine
US20070213313A1 (en) Direct process for the production of an amino acid dihydrochloride
KR0163956B1 (en) Process for direct isolation of captopril
CN111320712B (en) Synthesis method of sugammadex sodium intramolecular thioether impurity
JPH0717943A (en) Production of taurine
JPH0317096A (en) Production of dihydrate salt of tauroursodeoxycholic acid
JPH06184088A (en) Method for purifying taurine by ion exchange resin
JPH07233147A (en) Production of purified l-hydroxyproline
US4661625A (en) Synthesis and purification of d-propoxyphene hydrochloride
JP2917495B2 (en) Method for producing optically active 1,2-propanediamine
JPS60184054A (en) Method for purifying optically active lysine
JPS5849540B2 (en) Purification method of compound having both amino group and sulfonic acid group
JP2004196560A (en) Method for refining alkali iodide
JPH03190847A (en) Purification of 3,4-dichloronitrobenzene
JPS63233958A (en) Purification of aspartic acid
JPH08157444A (en) Production of aminoethanesulfonic acid
JPH023676A (en) Production of aminoalkylthiol sulfate
JPH01190661A (en) Purification of 4,4&#39;-dihydroxydiphenylsulfone
RU2537607C1 (en) Method of barium nitrate purification
KR830000025B1 (en) Chemical Degradation of Racemic Mandelic Acid
JPS6366821B2 (en)
JPS6122061A (en) Production of aminoethanesulfonic acid

Legal Events

Date Code Title Description
FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 8

Free format text: PAYMENT UNTIL: 20080623

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090623

Year of fee payment: 9

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100623

Year of fee payment: 10

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 10

Free format text: PAYMENT UNTIL: 20100623

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 11

Free format text: PAYMENT UNTIL: 20110623

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 12

Free format text: PAYMENT UNTIL: 20120623

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 12

Free format text: PAYMENT UNTIL: 20120623

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130623

Year of fee payment: 13

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130623

Year of fee payment: 13